Posted by Michael Wonder on 20 Oct 2023
Sumitomo Pharma and Pfizer in Canada receive Health Canada approval for Myfembree
19 October 2023 - Sumitomo Pharma Canada and Pfizer Canada today announced that Health Canada has granted a notice of compliance for Myfembree (relugolix, estradiol and norethindrone acetate tablets) for the management of moderate to severe pain associated with endometriosis in pre-menopausal women on 17 October 2023.
On 22 September 2023, Health Canada also approved Myfembree for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
